

Joey Mattingly

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1334564/publications.pdf>

Version: 2024-02-01

74
papers

690
citations

687363

13
h-index

677142

22
g-index

76
all docs

76
docs citations

76
times ranked

867
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cost of Self-Reported Penicillin Allergy: A Systematic Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1649-1654.e4.	3.8	93
2	Advancing the role of the pharmacy technician: A systematic review. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 94-108.	1.5	68
3	The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.		66
4	A Systematic Review of Leadership Definitions, Competencies, and Assessment Methods in Pharmacy Education. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 7520.	2.1	43
5	A Systematic Review of Entrepreneurship in Pharmacy Practice and Education. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 7233.	2.1	28
6	Pharmacists on Facebook: Online social networking and the profession. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2010, 50, 424-427.	1.5	25
7	Innovative patient care practices using social media. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2015, 55, 288-293.	1.5	22
8	Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?. <i>Pharmacoeconomics</i> , 2018, 36, 1093-1099.	3.3	21
9	Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 2059-2076.	1.0	21
10	Evaluating a Collaborative Approach to Improve Prior Authorization Efficiency in the Treatment of Hepatitis C Virus. <i>Quality Management in Health Care</i> , 2017, 26, 136-139.	0.8	20
11	Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2020, 38, 233-242.	3.3	19
12	What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism. <i>Patient</i> , 2019, 12, 631-638.	2.7	17
13	Examining patientâ€“provider relationship (PPR) quality and patient activation in the Medicare population. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 543-548.	2.9	16
14	Patient-Centered Drug Approval: The Role of Patient Advocacy in the Drug Approval Process. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 1078-1082.	0.9	15
15	Future of Patients in Healthcare Evaluation: The Patient-Informed Reference Case. <i>Value in Health</i> , 2019, 22, 545-548.	0.3	15
16	Evaluating the Changing Financial Burdens for Graduating Pharmacists. <i>American Journal of Pharmaceutical Education</i> , 2017, 81, 5990.	2.1	13
17	Penicillin skin testing in methicillin-sensitive staphylococcus aureus bacteremia: A cost-effectiveness analysis. <i>PLoS ONE</i> , 2019, 14, e0210271.	2.5	12
18	Beliefs and behaviors of professionally engaged pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2016, 56, 405-411.	1.5	9

#	ARTICLE	IF	CITATIONS
19	Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population. <i>Infectious Diseases and Therapy</i> , 2019, 8, 219-228.	4.0	9
20	Using 340B drug discounts to provide a financially sustainable medication discharge service. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 114-116.	3.0	9
21	Pharmapreneur â€œ Defining a Framework for Entrepreneurship in Pharmacy Education. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 7548.	2.1	9
22	A Review Exploring the Relationship Between Nursing Home Staffing and Antipsychotic Medication Use. <i>Neurology and Therapy</i> , 2015, 4, 169-175.	3.2	8
23	Measuring Up â€œ Defining the Quality of PharmD Programs. <i>American Journal of Pharmaceutical Education</i> , 2017, 81, 6071.	2.1	8
24	Exploring Patient-Reported Costs Related to Hepatitis C on the Medical Crowdfunding Page GoFundMeâ„¢. <i>PharmacoEconomics - Open</i> , 2021, 5, 245-250.	1.8	6
25	Pharmacy Practice around the World. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2009, 49, 4-10.	1.5	5
26	Publication of Cost-of-Illness Studies: Does Methodological Complexity Matter?. <i>Pharmacoeconomics</i> , 2016, 34, 1067-1070.	3.3	5
27	No filter: A characterization of #pharmacist posts on Instagram. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2017, 57, 318-325.	1.5	5
28	Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review. <i>Hepatology</i> , 2018, 67, 774-781.	7.3	5
29	Regulatory burden and salary for pharmacy technicians in the United States. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 623-626.	3.0	5
30	The Importance of Collaboration in Pursuit of Patient-Centered Value Assessment. <i>Patient</i> , 2020, 14, 381-384.	2.7	5
31	Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. <i>Pharmacoeconomics</i> , 2020, 38, 927-939.	3.3	5
32	The Economics of Penicillin Allergy Testing: Still Scratching the Value Surface. <i>Clinical Infectious Diseases</i> , 2021, 72, 939-941.	5.8	5
33	A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. <i>PharmacoEconomics - Open</i> , 2022, 6, 9-19.	1.8	5
34	Is There Room for Efficiency in Pharmacy Education?. <i>American Journal of Pharmaceutical Education</i> , 2018, 82, 7271.	2.1	5
35	Service description and analysis for an interprofessional discharge clinic within a primary care practice. <i>Journal of Interprofessional Care</i> , 2017, 31, 771-773.	1.7	4
36	Clinical Pharmacology-Driven Translational Research to Optimize Bedside Therapeutics of Sotalol Therapy. <i>Clinical and Translational Science</i> , 2019, 12, 648-656.	3.1	4

#	ARTICLE	IF	CITATIONS
37	Clinical and economic outcomes evaluated in Lyme disease: a systematic review. <i>Parasites and Vectors</i> , 2020, 13, 341.	2.5	4
38	Unseen Costs: The Direct and Indirect Impact of U.S. Immigration Policies on Child and Adolescent Health and Well-Being. <i>Journal of Traumatic Stress</i> , 2020, 33, 873-881.	1.8	4
39	Pharmacy's Call for Authorities to Aggressively Enforce Laws Addressing Price Gouging. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 952-955.	0.9	4
40	Food allergy treatment value: Child caregiver and patient perspectives. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 1038-1047.	2.6	4
41	Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?. <i>Annals of Pharmacotherapy</i> , 2017, 51, 961-969.	1.9	3
42	Relationship between regulatory barriers to entry and pharmacy technician wages. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 190-194.	3.0	3
43	60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad. <i>Research in Social and Administrative Pharmacy</i> , 2020, 17, 1489-1495.	3.0	3
44	Current Status and Best Practices of Shared Governance in US Pharmacy Programs. <i>American Journal of Pharmaceutical Education</i> , 2020, 84, ajpe7281.	2.1	3
45	A review of caregiver costs included in cost-of-illness studies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 1051-1060.	1.4	3
46	Implementing a Health Confidence Tool at Time of Discharge. <i>Patient</i> , 2019, 12, 163-165.	2.7	2
47	The economics of drug allergy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 395-400.	2.3	2
48	Changes in Cost-Effectiveness for Chronic Hepatitis C Virus Pharmacotherapy: The Case for Continuous Cost-Effectiveness Analyses. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 879-886.	0.9	2
49	Peer Review and Transparency in Evidence-Source Selection in Value and Health Technology Assessment. <i>Value in Health</i> , 2020, 23, 689-696.	0.3	2
50	Building confidence: Three-year evaluation of systematic progression of prescription verification on students' confidence during IPPE. <i>Currents in Pharmacy Teaching and Learning</i> , 2020, 12, 388-394.	1.0	2
51	Understanding authorized generics: A review of the published clinical data. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1489-1497.	1.5	2
52	Caregiver economics: A framework for estimating the value of the <sc>American Jobs Plan</sc> for a caring infrastructure. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 2370-2373.	2.6	2
53	Contextual Considerations and Recommendations for Estimating the Value of Alzheimer's Disease Therapies. <i>Pharmacoeconomics</i> , 2021, 39, 1101-1107.	3.3	2
54	Before We Talk About Student Debt Cancellation, Can We Talk About Interest Rates?. <i>American Journal of Pharmaceutical Education</i> , 2019, 83, 7761.	2.1	2

#	ARTICLE	IF	CITATIONS
55	Gender inequity and sexual harassment in the pharmacy profession: Evidence and call to action executive summary. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1375-1378.	1.0	2
56	Rescheduling of Combination Hydrocodone Products: Problems for Long-Term Care Practitioners. The Consultant Pharmacist, 2015, 30, 13-17.	0.4	1
57	Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents. Journal of Health Care for the Poor and Underserved, 2017, 28, 621-625.	0.8	1
58	Optimizing the role of pharmacy technicians in patient care settings: Measuring pharmacy technician impact on desired outcomes. Journal of the American Pharmacists Association: JAPhA, 2018, 58, 8-9.	1.5	1
59	Improving health determinants outside of the clinic does not mean outside of clinical science. Healthcare, 2019, 7, .	1.3	1
60	2019 Prescott Lecture: The case for authentic leadership. Journal of the American Pharmacists Association: JAPhA, 2019, 59, e12-e15.	1.5	1
61	Multiple Bosses: Challenges and suggestions to improve organizational environments in academic settings.. Innovations in Pharmacy, 2016, 7, .	0.6	1
62	Short-Stay Admissions Associated With Large COVID-19 Outbreaks in Maryland Nursing Homes. Gerontology and Geriatric Medicine, 2021, 7, 233372142110631.	1.5	1
63	Ensuring a high-quality and resilient supply chain of essential medications means paying more. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 573-576.	0.9	1
64	APhA2009 House of Delegates: Serving the Association and the profession. Journal of the American Pharmacists Association: JAPhA, 2009, 49, 474-479.	1.5	0
65	Speaking out. Pharmacy Today, 2012, 18, 4.	0.0	0
66	COST-OF-ILLNESS STUDIES: CONSIDERATIONS WHEN DESIGNING COI RESEARCH. Value in Health, 2016, 19, A272.	0.3	0
67	1216. Cost-Effectiveness of Penicillin Skin Allergy Testing in Methicillin-Sensitive Staphylococcus aureus (MSSA) Bacteremia. Open Forum Infectious Diseases, 2018, 5, S369-S369.	0.9	0
68	Researchers wanted: Improving the policy process with evidence. Journal of the American Pharmacists Association: JAPhA, 2018, 58, 334-335.	1.5	0
69	Elimination of Hepatitis C Virus Infection in Canada—It Is Achievable, But Is the Rest of the World Ready to Join in the Effort?. JAMA Network Open, 2020, 3, e204355.	5.9	0
70	Direct and Indirect Effects of Restrictive US Immigration Policies on Pharmacy Education. American Journal of Pharmaceutical Education, 2021, 85, 8534.	2.1	0
71	Pharmacoeconomics. , 2021, , 915-927.		0
72	Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review. Patient, 2021, 14, 471-484.	2.7	0

#	ARTICLE	IF	CITATIONS
73	Direct-to-consumer advertising (DTCA) and the advancement of the quadruple aim: a narrative review. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	0
74	Death, Taxes, and Tuition Increases. American Journal of Pharmaceutical Education, 2022, , 9068.	2.1	0